Results 11 to 20 of about 2,525 (153)

Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach.

PLoS ONE, 2020
Imipenem/cilastatin/relebactam is a β-lactam/β-lactamase inhibitor that has been recently FDA approved for complicated intra-abdominal and urinary tract infections under the brand name Recarbrio®.
Islam M Ghazi, Wasim S El Nekidy, Regan Asay, Paul Fimognari, Anthony Knarr, Mina Awad   +5 more
doaj   +4 more sources

Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections [PDF]

Drugs, 2021
Imipenem/cilastatin/relebactam (Recarbrio™) is an intravenously administered combination of the carbapenem imipenem, the renal dehydropeptidase-I inhibitor cilastatin, and the novel β-lactamase inhibitor relebactam. Relebactam is a potent inhibitor of class A and class C β-lactamases, conferring imipenem activity against many imipenem-nonsusceptible ...
Mansour, Hanine, Oweini, Ahmad E. L, Chahine, Elias B., Karaoui, Lamis R.   +3 more
openaire   +6 more sources

Klebsiella pneumoniae Susceptibility to Carbapenem/Relebactam Combinations: Influence of Inoculum Density and Carbapenem-to-Inhibitor Concentration Ratio

Biomedicines, 2022
The inoculum effect (IE) is a well-known phenomenon with beta-lactams. At the same time, the IE has not been extensively studied with carbapenem/carbapenemase inhibitor combinations.
Maria V. Golikova, Kamilla N. Alieva, Alla V. Filimonova, Vladimir A. Ageevets, Ofeliia S. Sulian, Alisa A. Avdeeva, Sergey V. Sidorenko, Stephen H. Zinner   +7 more
doaj   +1 more source

Combinación de antibióticos carbapenémicos con relebactam sobre enterobacterias productoras de carbapenemasas

Correo Científico Médico
Las enterobacterias productoras de carbapenemasas se han diseminado por todo el mundo y causan infecciones de alta mortalidad y morbilidad. Los antibióticos carbapenémicos se utilizan como último recurso frente a las infecciones graves producidas por ...
Washington Paúl Culqui Molina, Martha Elizabeth Loor Flores, Mónica Viviana Moscoso Silva   +2 more
doaj   +1 more source

New evidence in severe pneumonia: imipenem/ cilastatin/relebactam

Revista Española de Quimioterapia, 2022
Imipenem combined with beta-lactamase inhibitor relebactam (IMI/REL) has an extensive bactericidal activity against Gram-negative pathogens producing class A or class C beta-lactamases, not active against class B and class D. The phase 3 clinical trial (RESTORE-IMI-2), double-blind, randomized, evaluated IMI/REL vs.
Girón, R M, Ibáñez, A, Gómez-Punter, R M, Alarcón, T   +3 more
openaire   +4 more sources

Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies)

Microbiology Spectrum, 2022
Imipenem-relebactam is a novel β-lactam-β-lactamase inhibitor combination. We evaluated the in vitro activity of imipenem-relebactam and comparators against Enterobacterales clinical isolates recovered in 8 Spanish and 11 Portuguese intensive care units (
Marta Hernández-García, María García-Castillo, Germán Bou, Emilia Cercenado, Mercedes Delgado-Valverde, Antonio Oliver, Cristina Pitart, Jesús Rodríguez-Lozano, Nuria Tormo, José Melo-Cristino, Margarida F. Pinto, Elsa Gonçalves, Valquíria Alves, Ana Raquel Vieira, Elmano Ramalheira, Luísa Sancho, José Diogo, Rui Ferreira, Hugo Cruz, Catarina Chaves, Joana Duarte, Leonor Pássaro, Jazmín Díaz-Regañón, Rafael Cantón   +23 more
doaj   +1 more source

Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018–2020

BMC Microbiology, 2023
Background Carbapenem-resistant bacteria are an increasing problem in clinical practice; thus, it is important to identify β-lactamase inhibitors (e.g., relebactam) that can restore carbapenem susceptibility.
David W. Hilbert, C. Andrew DeRyke, Mary Motyl, Meredith Hackel, Katherine Young   +4 more
doaj   +1 more source

In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo-β-Lactamase-Producing Gram-Negative Bacteria

Antibiotics, 2023
Background: Despite the availability of new options (ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam and cefiderocol), it is still very difficult to treat infections caused by metallo-β-lactamase (MBLs)-producers resistant to aztreonam.
Cécile Emeraud, Sandrine Bernabeu, Laurent Dortet   +2 more
doaj   +1 more source

AmpC β-lactamase induction by avibactam and relebactam [PDF]

Journal of Antimicrobial Chemotherapy, 2017
Diazabicyclooctanes, e.g. avibactam and relebactam, are a new class of β-lactamase inhibitors. Their spectrum includes AmpC enzymes, but it is important to understand whether they also induce these enzymes.Levels of ampC mRNA were measured by RT-PCR during 4 h of exposure of Enterobacter cloacae, Citrobacter freundii and Pseudomonas aeruginosa (n = 5 ...
Livermore, David M, Jamrozy, Dorota, Mushtaq, Shazad, Nichols, Wright W, Young, Katherine, Woodford, Neil   +5 more
openaire   +4 more sources

In vitro activity of imipenem/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015–2017

Journal of Global Antimicrobial Resistance, 2020
Objectives: Antimicrobial resistance, including multidrug-resistance (MDR), is increasing, especially among Gram-negative bacilli. New agents are needed to treat infections caused by these pathogens.
James A. Karlowsky, Sibylle H. Lob, Krystyna M. Kazmierczak, Katherine Young, Mary R. Motyl, Daniel F. Sahm   +5 more
doaj   +1 more source